Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial

ObjectivesIn rheumatoid arthritis (RA), predictive biomarkers for subsequent radiographic progression (RP) could improve therapeutic choices for individual patients. We previously showed that the multibiomarker disease activity (MBDA) score in patients with newly diagnosed RA identified patients at...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatic & musculoskeletal diseases open 2016-01, Vol.2 (1), p.e000197-e000197
Main Authors: Hambardzumyan, Karen, Bolce, Rebecca J, Saevarsdottir, Saedis, Forslind, Kristina, Wallman, Johan K, Cruickshank, Scott E, Sasso, Eric H, Chernoff, David, van Vollenhoven, Ronald F
Format: Article
Language:English
Subjects:
Clinical Medicine
Klinisk medicin
Medical and Health Sciences
Medicin och hälsovetenskap
Reumatologi och inflammation
Rheumatoid Arthritis
Rheumatology and Autoimmunity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectivesIn rheumatoid arthritis (RA), predictive biomarkers for subsequent radiographic progression (RP) could improve therapeutic choices for individual patients. We previously showed that the multibiomarker disease activity (MBDA) score in patients with newly diagnosed RA identified patients at risk for RP. We evaluated the MBDA score at multiple time-points as a predictor of RP during 2 years of follow-up.MethodsA subset of patients with RA (N=220) from the Swedish Farmacotherapy (SWEFOT) trial were analysed for MBDA score, disease activity score of 28 joints (DAS28), C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) at baseline (BL), month 3 and year 1, for predicting RP based on modified Sharp/van der Heijde scores at BL, year 1 and year 2.ResultsPatients with persistently low MBDA (44) MBDA scores. Among methotrexate non-responders with a high MBDA score at BL or month 3, significantly more of those who received triple therapy had RP at year 2 compared with those who received antitumour necrosis factor therapy.ConclusionsMeasuring the MBDA score both before and during treatment in RA was useful for the assessment of individual patient risk for RP during 2 years of follow-up. In comparison with low CRP, ESR or DAS28, a low MBDA score at any time-point was associated with numerically lower proportions of RP.Trial registration numberNCT00764725.
ISSN:2056-5933
2056-5933
DOI:10.1136/rmdopen-2015-000197